This is a working overview of Plasma half-life, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-14 and is reviewed periodically as new material appears.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Although some worms have eyes (e.g. leeches, some polychaetes), earthworms do not. However, they do have specialized photosensitive cells called "light cells of Hess". These photoreceptor cells have a central intracellular cavity (phaosome) filled with microvilli. As well as the microvilli, there are several sensory cilia in the which are structurally independent of the microvilli. The photoreceptors are distributed in most parts of the epidermis, but are more concentrated on the back and sides of the worm. A relatively small number occur on the ventral surface of the first segment. They are most numerous in the prostomium, and reduce in density in the first three segments; they are very few in number past the third segment.
=== Subsidy reforms and economic policies === The Iranian government has, at times, cut subsidies on essential goods or tried to reform the subsidy system to address budget deficits. These changes often lead to sudden price hikes in food items. The subsidies have been replaced with in-kind transfers. For several decades, the Iranian government has regulated the prices of over 20 essential goods. These prices, known as administered prices, are determined by the Consumer and Producer Protection Organization (CPPO) in collaboration with the Iranian Parliament. The CPPO sets consumer prices below both reference (border) prices and producer prices, with the government budget absorbing the resulting financial gap. In 2007, food subsidies represented approximately 2.8 percent of Iran's GDP. These subsidies are primarily directed toward cereals, which account for 50 percent of the total, while other basic food items such as sugar, cooking oils, and baby formulas comprise an additional 25 percent. The remaining 25 percent is allocated to various goods, including paper, agricultural machinery, fertilizers, and pharmaceuticals. As part of the Targeted Subsidies Reform, the government raised bread prices by as much as 25 percent in December 2010. After this adjustment, the CPPO prohibited any further price increases and instituted regular market inspections to prevent public unrest that could arise from inflationary pressures.
In June 2025, President Trump brokered a peace deal between the Democratic Republic of Congo and Rwanda, with the U.S. getting "a lot of mineral rights". This potentially brings to an end a 30+ year conflict dating back to the 1994 Rwanda genocide. Each country had accused the other of financing and supporting rebel groups. On June 27, in a deal signed in the White House, each country pledged to end such support, allow the return of refugees, and create a joint security coordination mechanism aimed at resolving disputes. An estimated 6 million persons have died in this conflict, and Trump said that this deal ends "one of the worst wars anyone's ever seen". A critic said, "It risks reducing peace to a transactional exchange. Minerals are only one driver of conflict." Secretary of State Marco Rubio said, "This is an important moment after 30 years of war. President Trump is a president of peace. He really does want peace. He prioritizes it above all else." A former prime minister of the DR Congo, Joseph Kabila, expressed skepticism of the peace deal, saying that it was "nothing more than a trade agreement".
==== Overview ==== In July 2012, GSK pleaded guilty in the United States to criminal charges, and agreed to pay US$3 billion, in what was the largest settlement until then between the Justice Department and a drug company. The US$3 billion included a criminal fine of US$956,814,400 and forfeiture of US$43,185,600. The remaining US$2 billion covered a civil settlement with the government under the False Claims Act. The investigation was launched largely on the basis of information from four whistleblowers who filed qui tam (whistleblower) lawsuits against the company under the False Claims Act. The charges stemmed from GSK's promotion of the anti-depressants Paxil (paroxetine) and Wellbutrin (bupropion) for unapproved uses from 1998 to 2003, specifically as suitable for patients under the age of 18, and from its failure to report safety data about Avandia (rosiglitazone), both in violation of the Federal Food, Drug, and Cosmetic Act. Other drugs promoted for unapproved uses were two inhalers, Advair (fluticasone/salmeterol) and Flovent (fluticasone propionate), as well as Zofran (ondansetron), Imitrex (sumatriptan), Lotronex (alosetron) and Valtrex (valaciclovir). The settlement also covered reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program, and kickbacks to physicians to prescribe GSK's drugs. There were all-expenses-paid spa treatments and hunting trips for doctors and their spouses, speakers' fees at conferences, and payment for articles ghostwritten by the company and placed by physicians in medical journals.
Sources: en.wikipedia.org
=== Availability === Phenibut is approved in Russia, Ukraine, Belarus, Georgia and Latvia for medical use. It is not approved or available as a medication in other countries in the European Union, the United States, or Australia. In countries where phenibut is not a licensed pharmaceutical drug, it is sold online without a prescription as a "nutritional supplement". It is often used as a form of self-medication for social anxiety.
== Mechanism of toxicity == Mammalian and fungal membranes contain sterols, a primary membrane target for amphotericin B. Because mammalian and fungal membranes are similar in structure and composition, this is one mechanism by which amphotericin B causes cellular toxicity. Amphotericin B molecules can form pores in the host membrane as well as the fungal membrane. This impairment in membrane barrier function can have lethal effects. Ergosterol, the fungal sterol, is more sensitive to amphotericin B than cholesterol, the common mammalian sterol. Reactivity with the membrane is also sterol concentration dependent. Bacteria are not affected as their cell membranes do not usually contain sterols. Amphotericin B administration is limited by infusion-related toxicity. This is thought to result from innate immune production of proinflammatory cytokines.
The glycolytic end-product, pyruvate (plus NAD+) is converted to acetyl-CoA, CO2 and NADH + H+ within the mitochondria in a process called pyruvate decarboxylation. The resulting acetyl-CoA enters the citric acid cycle (or Krebs Cycle), where the acetyl group of the acetyl-CoA is converted into carbon dioxide by two decarboxylation reactions with the formation of yet more intra-mitochondrial NADH + H+. The intra-mitochondrial NADH + H+ is oxidized to NAD+ by the electron transport chain, using oxygen as the final electron acceptor to form water. The energy released during this process is used to create a hydrogen ion (or proton) gradient across the inner membrane of the mitochondrion. Finally, the proton gradient is used to produce about 2.5 ATP for every NADH + H+ oxidized in a process called oxidative phosphorylation.
{\displaystyle {\begin{aligned}{\ce {A + B <=> AB}};&\quad K_{\rm {AB}}={\frac {[{\ce {AB}}]}{{\ce {[A][B]}}}}\\{\ce {A + C <=> AC}};&\quad K_{\rm {AC}}={\frac {{\ce {[AC]}}}{{\ce {[A][C]}}}}\end{aligned}}}
Alternative methods of preservation, such as ice packing or laying the body on so called 'cooling boards', gradually lost ground to the increasingly popular and effective methods of embalming. By the mid-19th century, the newly emerging profession of businessmen-undertakers – who provided funeral and burial services – began adopting embalming methods as standard. Embalming became more common in the United States during the American Civil War, when servicemen often died far from home. The wish of families for their remains to be returned home for local burial and lengthy transport from the battlefield helped it become popular. The period from about 1861 is sometimes known as the funeral period of embalming and is marked by a separation of the fields of embalming by undertakers and embalming (anatomical wetting) for medical and scientific purposes. Dr Thomas Holmes received a commission from the Army Medical Corps to embalm the corpses of dead Union officers to return to their families. Military authorities also permitted private embalmers to work in military-controlled areas. The passage of Abraham Lincoln's body home for burial was made possible by embalming, and it brought wider public attention to the possibilities and potential of embalming. Until the early 20th century, embalming fluids often contained arsenic until it was supplanted by more effective and less toxic chemicals.
Sources: en.wikipedia.org
== History == The first YTX analog discovered, yessotoxin, was initially found in the scallop species Patinopecten yessoensis in the 1960s. Since then, numerous yessotoxin analogs have been isolated from shellfish and marine algae (including 45-hydroxyyessotoxin and carboxyyessotoxin). Initially, scientists wrongly classified YTXs in the group of diarrhetic shellfish poisoning (DSP) toxins along the lines of okadaic acid and azaspiracids. These types of toxins can cause extreme gastrointestinal upset and accelerate cancer growth. Once scientists realized YTXs did not have the same toxicological mechanism of action as the other toxins (protein phosphatase inhibitors), they were given their own classification.
=== 1995–1999: Origins of the feud === Both 50 Cent (Curtis Jackson) and Ja Rule (Jeffrey Atkins) emerged during the late 1990s growing up in two separate neighborhoods in Queens; with 50 Cent originating from South Jamaica and Ja Rule being from Hollis. Both rappers also began as drug dealers, in an effort to maintain financial stability for a period of time. Ja Rule’s career began in 1994, with him taking part in numerous projects and eventually resulting in him signing with Def Jam in late 1995 through his friendship with producer Irv Gotti. Meanwhile, 50 Cent developed a friendship with Jam Master Jay of Run DMC who sought to secure 50 a record deal in 1997. An early example of animosity starting between the two rappers likely began within that year; after Irv Gotti declined to offer 50 Cent a record deal with Def Jam, despite the insistence of Jam Master Jay. Ja Rule emerged with his first solo album Venni Vetti Vecci in June 1999, with the single "Holla Holla" becoming a hit, propelling the record to reach platinum certification. During this time, 50 Cent developed a friendship with production duo Trackmasters at the behest of Jam Master Jay, which culminated in 50 signing a deal with Columbia Records later that same year. 50 Cent claims that the feud began in 1999 after Ja Rule spotted him with a man who robbed him of his jewelry and also because Ja Rule was "trying to be 2Pac". However, Ja Rule claimed the conflict stemmed from a video shoot in Queens because 50 Cent did not like Ja Rule "getting so much love" from the neighborhood.
NAD(P)H dehydrogenase [quinone] 1 is an enzyme that in humans is encoded by the NQO1 gene. This protein-coding gene is a member of the NAD(P)H dehydrogenase (quinone) family and encodes a 2-electron reductase (enzyme). This FAD-binding protein forms homodimers and performs two-electron reduction of quinones to hydroquinones and of other redox dyes. It has a preference for short-chain acceptor quinones, such as ubiquinone, benzoquinone, juglone and duroquinone. This gene has an important paralog NQO2. This protein is located in the cytosol. NQO1 enzyme expression can be induced by dioxin and inhibited by dicoumarol.
=== Toxicology data === In the 1990s, fialuridine (FIAU) was investigated in clinical trials. The first trial was a 10-day trial in which 43 patients, who were infected with HIV and hepatitis B, demonstrated effective antiviral activity. A subsequent second dose-ranging study was done on 24 patients with hepatitis B over a period of four weeks. The second trial showed significant viral suppression at intermediate doses. However, patients later relapsed, meaning that the viral infection had returned. A longer, 6-month NIH-sponsored, third trial was planned to be conducted, but severe toxicity emerged at patients who had participated in the second trial. Many severe and fatal adverse effects were reported, including lactic acidosis, acute liver failure, peripheral neuropathy, multiple organ failure, and mitochondrial toxicity. A 60-year-old patient died from liver failure and lactic acidosis four months after the second trial. During the third trial, many patients experienced unpleasant side effects such as nausea and vomiting to such an extent that the researchers decided to end the trial. A theory put forward by Dr. Yung-Chi Chang of Yale University in 1991, which hypothesize that FIAU damaged the mitochondrial DNA, thereby giving rise to delayed toxicity. Urgent attempts were subsequently made to counteract the loss of mitochondria. However, by July 16, three patients had died, of whom two had already received a liver transplant and one was waiting for one. By August 1993, two more patients reported to be gravely ill and two other patients had also died.
GLaDOS (Genetic Lifeform and Disk Operating System) is a rampant artificial intelligence computer system that controls Aperture Laboratories, and is the primary antagonist for the Portal series. She is voiced by Ellen McLain. She awakens the player-character Chell in the first game, tasking her through the dangerous testing course, but Chell manages to escape and appears to destroy her, though later revealed to have had her personality stored within a black box. Within the second game, Wheatley accidentally reawakens GLaDOS, and eventually convinces Chell to initiate a core transfer to replace her with himself. GLaDOS, placed into a module powered by a potato battery, is forced to work with Chell to depose Wheatley from power before the Aperture facility is destroyed. While exploring the older sections of the facility with GLaDOS's potato battery form (known informally as "PotatOS" by fans), it is revealed that her consciousness is based, at least in part, on an uploaded version of Cave Johnson's assistant, Caroline. Caroline was unwilling to be uploaded to a computer, but was forced to do so by Cave. This potentially contributed to GLaDOS's homicidal tendencies, alongside the mental adjustments and tweaking performed by the scientists working on her. In the tie-in comic Portal 2: Lab Rat, it is revealed that the personality cores, such as Wheatley, were attached to GLaDOS in an attempt to manage and control her by acting as an artificial "conscience." Discussing the morality core, scientist Doug Rattmann quips, "You can always ignore your conscience."
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.